Project UpdateMay 4, 2026, 01:00 AM
Molecular Partners to Present MP0712 Radio-DARPin Data at 3 Conferences
AI Summary
Molecular Partners AG announced its attendance and presentations on its lead Radio-DARPin candidate MP0712 at three upcoming scientific conferences in May 2026. The presentations will cover the molecular characteristics, preclinical insights, clinical development, and first-in-human insights of MP0712 for targeted anti-DLL3 radiotherapy of small cell lung cancer (SCLC) and opportunities for future candidates. The company is a clinical-stage biotech pioneering DARPin therapeutics for medical challenges, particularly in cancer.
Key Highlights
- Molecular Partners to present on its lead Radio-DARPin candidate MP0712 at three upcoming scientific conferences.
- NIH National Cancer Institute SCLC Consortium Meeting presentation on MP0712's molecular characteristics on May 7.
- PEGS Boston presentation on advancing Radio-DARPin therapeutics from preclinical to clinical on May 13.
- Antibody & Engineering Therapeutics presentation on first-in-human insights with MP0712 on May 29.
- MP0712 is a clinical-stage ²¹²Pb-based Radio-DARPin candidate for targeted anti-DLL3 radiotherapy of SCLC.
- Molecular Partners is a clinical-stage biotech developing DARPin therapeutics for cancer patients.
Price Impact
More from MOLN